Next, we used APN-mab005, a newly developed monoclonal antibody (an antibody drug that blocks tau aggregation and propagation52) that recognizes specifically aggregated tau, mostly tau species segregated into the synaptic/membrane compartments in synaptosomes prepared from AD brains. Here, MAPT is linked to Alzheimer disease.